Navigation Links
GeoVax to Present at the BIO CEO & Investor Conference 2009
Date:1/28/2009

ATLANTA, Jan. 28 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, publicly traded biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that Robert McNally, Ph.D., Chief Executive Officer and President, will present a corporate update at the Eleventh Annual BIO CEO & Investor Conference 2009, held at the Waldorf-Astoria Hotel, in New York, on February 9-10, 2009.

The BIO CEO & Investor Conference is the preeminent gathering of cutting edge biotechnology companies, represented by senior executives, presenting their achievements to institutional investors, industry analysts and portfolio senior executives. Presenting companies were selected through a competitive screening process with a focus on their potential to deliver near-term clinical accomplishments in areas of unmet medical need. The expected attendance at the conference will include representatives from nearly 80 investment firms with a specific interest in life science companies.

Dr. McNally will present an overview of GeoVax's vaccine technology and will report the latest progress on the Company's Phase 2a preventative human vaccine trial and plans for upcoming therapeutic human vaccine trials. Dr. McNally also plans to meet one-on-one with current and prospective GeoVax investors, analysts, investment bankers and other potential Company partners.

"Having met significant milestones entering Phase 2a human trials with our highly promising HIV-1/AIDS vaccines and with our plans to launch our therapeutic human trials in the near future, the time has arrived for the Biotech sector and its respective investment audience to learn about our progress. We feel privileged to be among a select group of biotech companies showcasing our technologies to an elite group of interested investment
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
9. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
10. Avicena Group to Present at Noble Financial Conference
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Adult stem cells that are required ... not magical. However, many current regenerative medicine ... if they were magical. , Many current clinical ... “stem cell tourism,” are evaluating heterologous tissue stem ... regenerative medicine therapies. In reality, these are not ...
(Date:7/22/2014)... LAKES, N.J. , July 22, 2014 The ... BDX ) has declared a quarterly dividend of ... to holders of record on September 9, 2014. The indicated ... About BD BD is a leading medical technology ... of the world,s most pressing and evolving health needs. Our ...
(Date:7/22/2014)... metal nanoparticles in water with ultrasound and they,ll spin ... No one yet knows exactly. But researchers at the ... their speedand it,s fast. At up to 150,000 revolutions ... any nanoscale object submerged in liquid ever reported. , ... the possibility that they could be used not only ...
(Date:7/22/2014)... Nuclear reactors are used to produce electricity ... chain reaction in nuclear reactors is used to create ... a power- generating turbine. Currently nuclear reactors are used ... production. Nuclear reactor market is expected to grow in ... nuclear reactor projects. , Early buyers will receive 10% ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 3
... Arpida Ltd,(SIX: ARPN) announced today its financial results for the year ending 31,December ... - Setback in regulatory process for intravenous iclaprim in US, ... - Top-line results of "intravenous-to-oral" Phase II trial with oral, ... change, - Share placing, Cash ...
... Feb. 25 Cerimon Pharmaceuticals, Inc., announced ... its once-daily topical diclofenac sodium patch Phase III program. ... Phase III clinical studies with Cerimon,s diclofenac patch. ... Cerimon,s diclofenac patch compared to placebo for the treatment ...
... SAN DIEGO and MONTREAL, Feb. 25 Speid ... consultancy firm today announced that it has entered ... success rates of new drug compounds using Genizon,s ... climate in which innovative pharmaceutical and biotechnology companies ...
Cached Biology Technology:Arpida Announces Full Year 2008 Financial Results 2Arpida Announces Full Year 2008 Financial Results 3Arpida Announces Full Year 2008 Financial Results 4Arpida Announces Full Year 2008 Financial Results 5Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain 2Speid & Associates Partners With Genizon BioSciences to Reduce Attrition Rates of New Drug Compounds 2
(Date:7/22/2014)... research team from the National Institute of Standards ... has demonstrated a dramatically improved technique for analyzing ... vibration "signatures." The new NIST technique is an ... spectroscopy, but one that delivers signals that are ... scattering, and 100 times stronger than obtained from ...
(Date:7/22/2014)... of nanomaterials for application in devices may be addressed ... conducted by scientists from the National University of Singapore ... and low cost technique involving a focused laser beam, ... Haur from the Department of Physics at the NUS ... different types of materials can be controlled and modified, ...
(Date:7/22/2014)... milk helps make their bones strong or that fish is food ... if something is good for us, it must surely taste bad? ... Research , when children hear about the benefits of healthy food, ... food is presented to children as making them strong or as ... read or count, they would conclude the food is not as ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3NUS scientists use low cost technique to improve properties and functions of nanomaterials 2NUS scientists use low cost technique to improve properties and functions of nanomaterials 3
... 2010): Today, the Association for Molecular Pathology (AMP) submitted written ... the National Institutes of Health (NIH) for its Genetic Test ... to formulate a comprehensive response to the RFI. "With ... setting, AMP is able to inform the NIH on the ...
... While pundits write obituaries for the 2010 climate bill, ... the world. We are losing species and ecosystems are unraveling ... We need new tools and strategies to deal with these ... to announce the launch of their new Climate Adaptation Knowledge ...
... PHILADELPHIAIn 1824, three years before he began to publish his ... Audubon (1785-1851), the eminent artist of American birds and animals, ... the design for a New Jersey bank note. Although the ... in two separate diary entries, no one has ever been ...
Cached Biology News:AMP responds to Genetic Test Registry request for information 2CAKE offers way forward for climate change adaptation 2Discovered: Audubon's first engraving of a bird 2
...
... Forma Incubated Orbital Shakers combine high ... performance and ease of use. The ... allowing the unit to run at ... The unit's class-leading temperature range is ...
The 891 45° Fixed Angle Rotor is designed to provide aerosol containment and can be removed from a centrifuge (seal entact) and opened under an environmental hood....
... have the durability to run ... and the uniformity and contamination ... applications. Heavily built with ... stackers are designed for ease ...
Biology Products: